AFFiRiS biotechnology company has entered into a definitive agreement with AC Immune in regards to the sale of its entire portfolio of anti-alpha-synclein immunotherapies in exchange for shares in AC Immune with regard to all
AFFiRiS biotechnology company has entered into a definitive agreement with AC Immune in regards to the sale of its entire portfolio of anti-alpha-synclein immunotherapies in exchange for shares in AC Immune with regard to all